Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Feb 1;53(2):e269-e281.
doi: 10.1097/CCM.0000000000006564. Epub 2025 Feb 21.

Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial

Thiago M L Almeida  1   2   3   4 , Flávio G R Freitas  1   2   3   5 , Rodrigo C Figueiredo  6 , Sandra G Houly  7 , Luciano C P Azevedo  3 , Alexandre B Cavalcanti  3 , Lucas P Damiani  3 , Bianca S Svicero  1 , Maria A Souza  1 , Cíntia L S Bustamante  6 , Fernando J S Ramos  1   2   3 , Rafael S V Alves  1   2 , Fernanda C Atallah  1 , Míriam Jackiu  1 , Eduardo S Pacheco  1 , Raysa C Schmidt  1   2 , Felipe S C Serra  1 , Daniere Y V Tomotani  1   3 , Fernando G Zampieri  1   3 , Flávia R Machado  1   2   3 ; BRICNET
Affiliations
Clinical Trial

Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial

Thiago M L Almeida et al. Crit Care Med. .

Abstract

Objectives: Platelets play a critical role in the inflammatory response and coagulation. We aimed to evaluate whether the use of acetylsalicylic acid (ASA) would reduce the intensity of organ dysfunction in septic patients.

Design: Randomized, blinded, parallel-group, placebo-controlled trial.

Setting: Five general ICUs in Brazil.

Patients: Adults with sepsis for no longer than 48 hours who had at least one severe organ dysfunction (lactate > 4 mmol/L, platelets < 100,000/mm3, Pao2/Fio2 ratio < 200, or septic shock).

Interventions: Patients were randomized to receive 200 mg of ASA or placebo for 7 days.

Measurements and main results: The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score between day 0 and day 7 or date of discharge/death. Safety outcomes were major bleeding and the number of blood transfusions within 14 days. The planned sample size was 218 with interim safety analyses after enrolling 109 and 163 patients. The study was discontinued due to higher frequency of major bleeding in the ASA group. We included 166 patients (ASA: 82 patients, placebo: 84). In the adjusted analysis, there was no difference in the SOFA change between the groups (mean placebo to ASA group difference, 0.60; 95% CI, -0.55 to 1.75; p = 0.30). There were no differences in any of the secondary outcomes. In the intervention group, there were a higher number of serious adverse events (9 [11%] vs. 1 [1.2%]; p = 0.009) and major bleeding (8 [8.5%] vs. 1 [1.2%]; p = 0.02).

Conclusions: In this population of septic patients, ASA did not reduce the intensity of organ dysfunction. ASA increased the risk of severe bleeding compared with placebo.

Trial registration: ClinicalTrials.gov NCT01784159.

PubMed Disclaimer

Conflict of interest statement

Dr. Azevedo received funding from Merck Sharp & Dohme, Baxter, Nestle, and Biolab Farma. Drs. Cavalcanti and Machado disclosed off-label use of aspirin. Drs. Svicero and Machado disclosed government work. Dr. Bustamante received support for article research from the National Institutes of Health. Dr. Machado received support for article research from Fundação de Amparo a Pesquisa do Estado de São Paulo (2020/02261-0). The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200–211
    1. Levi M, van der Poll T: Coagulation and sepsis. Thromb Res. 2017; 149:38–44
    1. Iba T, Levy JH, Levy JH: Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018; 16:231–241
    1. Flato UA, Buhatem T, Merluzzi T, et al.: New anticoagulants in critical care settings. Rev Bras Ter Intensiva. 2011; 23:68–77
    1. van der Poll T, Parker RI: Platelet activation and endothelial cell dysfunction. Crit Care Clin. 2020; 36:233–253

Publication types

Associated data

LinkOut - more resources